Lipocine Inc. (NASDAQ:LPCN) shares moved up 1.95% in last trading session and ended the day at $9.93. LPCN has a return on assets of -45.30%. Lipocine Inc. (NASDAQ:LPCN) quarterly performance is -30.95%.
On 16 February, Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, announced top-line results from its multi-dose pharmacokinetic (“PK”) dose finding clinical study of LPCN 1107, its oral hydroxyprogesterone caproate (“HPC”) product candidate for the prevention of preterm birth.
Omega Protein Corporation (NYSE:OME) ended the last trading day at $21.81. Company weekly volatility is calculated as 4.46% and price to cash ratio as 606.32. Omega Protein Corporation (NYSE:OME) showed a weekly performance of 3.86%.
Pivotal Research upgraded shares of Omega Protein Co. (NYSE:OME) from a hold rating to a buy rating in a research report sent to investors on Wednesday morning, The Fly reports. Pivotal Research currently has $23.00 price objective on the stock, up from their previous price objective of $19.00.
On 18 February, The Children’s Place, Inc. (NASDAQ:PLCE) shares moved up 1.48% and was closed at $66.40. PLCE EPS growth in last 5 year was 1.49%. The Children’s Place, Inc. (NASDAQ:PLCE) year to date (YTD) performance is 20.29%.
On February 12, 2016, the Board of Directors of The Children’s Place, Inc. (NASDAQ:PLCE) approved an amendment to the Company’s Bylaws effective as of such date to provide proxy access rights to stockholders. Pursuant to this amendment, the Company will include nominees in its proxy materials for up to 20% of the Board of Directors, but not less than two directors, proposed by a stockholder or a group of up to 20 stockholders who have continuously owned 3% or more of the Company’s common stock for three years or more.
Higher One Holdings, Inc. (NYSE:ONE) shares fell -1.19% in last trading session and ended the day at $4.14. ONE Gross Margin is 49.20% and its has a return on assets of -0.70%. Higher One Holdings, Inc. (NYSE:ONE) quarterly performance is 41.30%.
Higher One Holdings, Inc. (NSYE:ONE) announced financial results for the fourth quarter and full year for 2015. The Company reported fourth quarter 2015 gross revenue of $49.4 million, compared to $53.1 million in the fourth quarter 2014, and full year revenue of $204.2 million, compared to $214.4 million in 2014. Non-GAAP adjusted diluted EPS was $0.10 for the quarter and $0.44 for the full year 2015, compared to $0.14 for the fourth quarter and $0.59 for the full year of 2014.
China Biologic Products, Inc. (NASDAQ:CBPO) caters to the Healthcare space. It has a net profit margin of 37.40% and weekly performance is 6.44%. On the last day of trading company shares ended up at $114.51.
China Biologic Products, Inc. (NASDAQ:CBPO) a leading fully integrated plasma-based biopharmaceutical company in China, announced that the Company plans to release fourth quarter and fiscal year 2015 financial results on Thursday, February 25, 2016 after the market closes.
Leave a Reply